Metformin, a promising oral antihyperglycemic for the treatment of noninsulin-dependent diabetes mellitus

Pharmacotherapy

Volumn 17, Issue 1, 1997, Pages 62-73

  Wildasin, Elena M ^a   Skaar, Debra J ^a   Kirchain, William R ^a   Hulse, Michelle ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; METFORMIN; SULFONYLUREA DERIVATIVE;

CLINICAL TRIAL; CORONARY RISK; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE UTILIZATION; HUMAN; HYPERINSULINISM; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; REVIEW; TREATMENT PLANNING;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN;

EID: 0031037037     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Anonymous. Metformin. Phase III Drug Profiles 1994;4:1-15.
2. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 1993;16:621-9.
3. Shamoon H. Pathophysiology of diabetes - a review of selected recent developments and their impact on treatment. Drugs 1992;44:1-12.
4. Stout RW. Insulin and atheroma - 20-year perspective. Diabetes Care 1990;13:631-54.
5. Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care 1990;13:696-704.
6. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992;340:925-9.
7. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
8. Donnelly R, Morris AD. Drugs and insulin resistance: clinical methods of evaluation and new pharmacological approaches to metabolism. Br J Clin Pharmacol 1994;37:311-20.
9. Campbell IW. Management of type 2 diabetes mellitus with special reference to metformin therapy. Diabete Metab 1991;17:191-6.
10. Bailey CJ. Metformin - an update. Gen Pharmacol 1993;24:1299-1309.
11. Hermann LS. Metformin: a review of its pharmacological properties and therapeutic use. Diabete Metab 1979;5:233-45.
12. Hermann LS. Biguanides and sulfonylureas as combination therapy in NIDDM. Diabetes Care 1990;13:37-41.
13. Lebovitz HE. Oral antidiabetic agent - the emergence of α-glucosidase inhibitors. Drugs 1992;44:21-8.
14. Berger W. Incidence of severe side effects during therapy with sulfonylureas and biguanides. Horm Metab Res 1985; 15(suppl):111-15.
15. Colwell JA. Is it time to introduce metformin in the US? Diabetes Care 1993;16:653-5.
16. Peters AL, Davidson MB. Treatment of poorly controlled type 2 diabetes. Compr Ther 1994;20:321-5.
17. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992;15:755-72.
18. Duhault J, Lavielle R. History and evolution of the concept of oral therapy in diabetes. Diabetes Res Clin Pract 1991;14:S9-14.
19. Cavallo-Perin P, Aluffi E, Estivi P, et al. The hyperlactatemic effect of biguanides: a comparison between phenformin and metformin during a 6-month treatment. Eur Rev Med Pharmacol Sci 1989;11:45-9.
20. Wiholm BE, Myrhed M. Metformin-associated lactic acidosis in Sweden 1977-1991. Eur J Clin Pharmacol 1993;44:589-91.
21. Bristol-Myers Squibb. Glucophage (metformin hydrochloride) package insert. Princeton, NJ; 1995.
22. Bloomgarden ZT. Treatment issues for NIDDM. Diabetes Care 1994;17:1078-84.
23. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-4.
24. Perriello G, Misericordia P, Volpi E, et al. Acute anti-hyperglycemic mechanisms of metformin in NIDDM - evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994;43:920-8.
25. Johnson AB, Webster JM, Sum CF, et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism 1993;42:1217-22.
26. Dornan TL, Heller SR, Peck GM, Tattersall RB. Double blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care 1991;14:342-4.
27. Hollenbeck CB, Johnston P, Varasteh BB, Chen YDI, Reaven GM. Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridemia and non-insulin dependent diabetes by glucose tolerance test criteria. Diabete Metab 1991;17:483-9.
28. Teupe B, Bergis K. Prospective randomized two-year clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete Metab 1991;17: 213-17.
29. DeFronzo R, Goodman A, and the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:541-9.
30. Hermann LS, Karlsson JE, Sjorstrand A. Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles. Eur J Clin Pharmacol 1991;41:263-5.
31. Hermann LS, Schersten B, Bitzen P, Kjellstrom T, Lindgarde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations - a double-blind controlled study. Diabetes Care 1994;17:1100-9.
32. Clarke BF, Duncan LJP. Combined metformin-chlorpropamide therapy in 108 diabetic sulphonylurea failures. Lancet 1965;1:1248-51.
33. DeFronzo RA, Goodman A, and the Multicenter Metformin Study Group. Combined metformin/glyburide treatment in NIDDM patients not optimally responding to maximum dose sulfonylurea: results of a multicenter trial. Diabetes 1993;42(suppl 1):146A.
34. Gregorio F, Ambrosi F, Marchetti P, et al. Low dose metformin in the treatment of type II non-insulin-dependent diabetes: clinical and metabolic evaluations. Acta Diabetol 1990;27:139-55.
35. Haupt E, Knick B, Koschinsky T, Liebermeister H, Schneider J, Hirche H. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabete Metab 1991;17: 224-31.
36. Marena S, Tagliaferro V, Montegrosso G, Pagano A, Scaglione L, Pagano G. Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes. Diabete Metab 1994;20:15-19.
37. Reaven GM, Johnston P, Hollenbeck CB, et al. Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab 1992;74:1020-6.
38. Klein W. Sulfonylurea-metformin combination versus sulfonylurea-insulin combination in secondary failures of sulfonylurea monotherapy - results of a prospective randomized study in 50 patients. Diabete Metab 1991;17:235-40.
39. Groop L, Widen E. Treatment strategies for secondary sulfonylurea failure - should we start insulin or add metformin? Is there a place for intermittent insulin therapy? Diabete Metab 1991;17:218-23.
40. Vigneri R, Trischitta V, Italia S, Mazzarino S, Rabuazzo MA, Squatrito S. Treatment of NIDDM patients with secondary failure to glyburide: comparison of the addition of either metformin or bed-time NPH insulin to glyburide. Diabete Metab 1991;17:232-4.
41. Trischitta V, Italia S, Mazzarino S, et al. Comparison of combined therapies in treatment of secondary failure to glyburide. Diabetes Care 1992;15:539-42.
42. Widen EIM, Eriksson JG, Groop LC. Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes 1992;41:354-8.
43. Riccio A, Del Prato S, De Kreutzenberg SV, Tiengo A. Glucose and lipid metabolism in non-insulin-dependent diabetes -effect of metformin. Diabete Metab 1991;17:180-4.
44. Elkeles RS. The effects of oral hypoglycaemic drugs on serum lipids and lipoproteins in non-insulin-dependent diabetes (NIDDM). Diabete Metab 1991;17:197-200.
45. Chan JCN, Tomlinson B, Critchley JAJH, Cockram CS, Walden RJ. Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients. Diabetes Care 1993;16:1035-8.
46. Grant PJ, Stickland MH, Booth NA, Prentice CRM. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabet Med 1991;8:361-5.
47. Grant PJ. The effects of metformin on the fibrinolytic system in diabetic and non-diabetic subjects. Diabete Metab 1991;17:168-73.
48. Pentikainen PJ, Voutilainen E, Aro A, et al. Cholesterol lowering effect of metformin in combined hyperlipidemia: placebo controlled double blind trial. Ann Med 1990;22: 307-12.
49. Campbell IW. Metformin and the sulphonylureas: the comparative risk. Horm Metab Res 1985;15(suppl):105-10.
50. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 1987;23:545-51.
51. Abramowicz M, ed. Metformin for non-insulin-dependent diabetes mellitus. Med Lett 1995;37(948):41-2.